Valuation: Moderna, Inc.

Market Cap 23.62B 20.44B 19.09B 17.52B 32.93B 2,249B 33.43B 223B 87.75B 1,126B 88.69B 86.76B 3,729B P/E 2026 *
-6.9x
P/E 2027 * -12.1x
Enterprise Value 19.97B 17.29B 16.14B 14.81B 27.84B 1,901B 28.27B 189B 74.2B 952B 74.99B 73.36B 3,153B EV / Sales 2026 *
9.48x
EV / Sales 2027 * 8.79x
Free-Float
92.75%
Yield 2026 *
-
Yield 2027 * -
1 day+3.89%
1 week+0.89%
Current month+0.89%
1 month-23.62%
3 months+6.08%
6 months+44.84%
Current year+86.73%
1 week 46.73
Extreme 46.73
51.12
1 month 46.73
Extreme 46.73
68.31
Current year 25.4
Extreme 25.405
73.41
1 year 19.48
Extreme 19.482
73.41
3 years 19.48
Extreme 19.482
154.76
5 years 19.48
Extreme 19.482
423.85
10 years 19.48
Extreme 19.482
423.85
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%+0.89% - - 23.62B
+1.59%+2.85%+39.32%+0.52% 78.32B
+2.77%+4.78%-0.98%+28.10% 51.1B
-0.84%+0.09%+20.92%+175.02% 49.18B
-0.13%+7.42%-49.33%-50.09% 44.71B
+0.80%+2.46%+59.13%-24.15% 30.72B
+1.84%+0.87%+53.80%+86.83% 24.44B
+9.86%+7.94%+126.53%-40.68% 23.62B
+4.29%+9.40%+3.95%+230.49% 21.05B
+1.66%-3.70%+66.13%+121.72% 16.61B
Average +2.57%+4.08%+35.50%+58.64% 37.75B
Weighted average by Cap. +2.01%+4.29%+26.94%+44.55%

Financials

2026 *2027 *
Net sales 2.11B 1.82B 1.7B 1.56B 2.94B 201B 2.98B 19.93B 7.82B 100B 7.91B 7.74B 333B 2.43B 2.1B 1.96B 1.8B 3.39B 231B 3.44B 22.97B 9.02B 116B 9.12B 8.92B 383B
Net income -3.38B -2.92B -2.73B -2.51B -4.71B -322B -4.78B -31.97B -12.55B -161B -12.69B -12.41B -533B -1.92B -1.67B -1.56B -1.43B -2.68B -183B -2.72B -18.2B -7.15B -91.71B -7.22B -7.07B -304B
Net Debt -3.65B -3.16B -2.95B -2.71B -5.09B -347B -5.16B -34.52B -13.56B -174B -13.7B -13.4B -576B -2.27B -1.97B -1.84B -1.68B -3.17B -216B -3.21B -21.49B -8.44B -108B -8.53B -8.34B -359B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-08-07 €49.59 +3.89% 336
26-08-06 €47.73 -4.20% 672
26-08-05 €49.82 +0.60% 431
26-08-04 €49.53 +1.20% 742
26-08-03 €48.94 -0.43% 367
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
59.17USD
Average target price
50.84USD
Spread / Average Target
-14.07%

Quarterly revenue - Rate of surprise